The University of New Mexico Hospital (locally known as either University Hospital, UNM Hospital, or shortened to UNMH) is a public teaching hospital located in Albuquerque, New Mexico, immediately north of the main campus of the University of New Mexico. The hospital is the only Level I trauma center in the state of New Mexico, and also houses the only certified burn unit and designated stroke center in the state. In addition, UNMH also contains the only children's hospital in New Mexico, and is the state's sole source of 13 pediatric sub-specialties. As a safety net hospital, UNMH serves a large percentage of the uninsured and under-insured population of the state. The hospital is the main teaching facility for the University of New Mexico School of Medicine.
Objectives Growing complexity in oncology care necessitates innovative organizational models in outpatient and home-based settings. While oncology advanced practice nurses (APNs) are integrated into the French healthcare system, evidence on their routine implementation remains limited. This study evaluated an oncology APN–led care pathway across Day Hospital (DH) and Hospital-at-Home (HaH) settings, describing patient profiles, treatment characteristics, and organizational determinants of HaH utilization. Methods We conducted a retrospective study of patients managed by an oncology APN between November 2019 and May 2025 across DH and HaH settings. Sociodemographic, cancer-related, treatment-related, and care delivery data were extracted from electronic medical records and APN activity logs. DH and HaH patients were compared for profiles, follow-up characteristics, and organizational constraints. Results Overall, 209 patients were included: 64% women, median age 64 years (range 21-93). The most frequent cancers were breast (41.6%), lung (29.8%), and glioma (6.7%). About 116 patients were managed in DH and 93 in HaH; HaH patients lived significantly closer to the hospital. Treatments were mainly immunotherapies (53.5%) and anti-HER2 therapies (36.3%), administered every 21 days. Adoption of the APN-led pathway increased progressively over time, with the APN managing 107 patients simultaneously in 2024. Main barriers to HaH access were organizational constraints related to provider availability and eligibility criteria. Conclusions This study provides real-world evidence on the organizational functioning of an oncology APN–led care pathway across hospital and home-based settings. The findings highlight adoption dynamics, organizational determinants of HaH access, and the central coordinating role of the APN.
Background Drug-coated balloons (DCBs) are established for in-stent restenosis, whereas their role in de novo coronary lesions continues to evolve. Large-scale data on real-world adoption for native lesions remain limited. Methods We analyzed the nationwide National Registry of Invasive Cardiology Procedures (ORPKI), including all percutaneous coronary interventions (PCI) performed in Poland between January 2020 and December 2025. Procedures for in-stent restenosis, chronic total occlusion, and plain balloon angioplasty without drug coating were excluded. The final cohort comprised 504,501 PCI procedures for de novo native coronary lesions, classified as DCB-only, stent-only, or hybrid (DCB plus stent). Temporal trends, clinical and angiographic characteristics, and factors independently associated with a DCB-only strategy were assessed. Results DCB use increased more than eightfold, from 0.55% of procedures in 2020 to 4.78% in 2025 ( P < .001); DCB-only use rose from 0.37% to 4.12%, and hybrid use from 0.20% to 0.66%. The increase was most pronounced in nonmain coronary segments (0.8%-9.5%). Compared with stent-treated procedures, DCB-only procedures more often involved diabetes, chronic kidney disease, previous myocardial infarction, previous PCI, and previous coronary artery bypass grafting (CABG), and chronic coronary syndromes. In multivariable analysis, nonmain segment location, previous PCI, previous CABG, diabetes, chronic kidney disease, and the use of optical coherence tomography, intravascular ultrasound, and fractional flow reserve were independently associated with a DCB strategy. Conclusions DCB use for de novo coronary lesions increased markedly between 2020 and 2025, with a preference for nonmain, distal, and side-branch segments and for clinically complex patients, often alongside intracoronary imaging or physiological assessment. (Am HeartJ 2027;303:107609.)
Mutations in the RNA-binding protein roquin-1 are known to result in humoral autoimmunity. Heissmeyer and colleagues show that MALT1 cleavage of roquin and regnase-1 downstream of TCR signaling releases cooperatively repressed targets to promote T H 17 cell differentiation
Chronic prurigo (CPG) is a chronic neuroinflammatory skin disease characterized by persistent itch, repeated scratching, and the presence of multiple skin lesions. CPG is a highly burdensome disease that significantly impairs patients’ quality of life. The objective of these consensus recommendations is to summarize available evidence and provide standardized guidance for the diagnosis and management of patients with CPG. These recommendations were developed using a Delphi methodology, conducted over two rounds of online voting by the participation of 23 Portuguese dermatologists. The strength of consensus was defined as strong consensus (≥ 95
Abstract Background Reduced intensity and diversity of microbial stimulation and decreased intake of anti-inflammatory ω-3 polyunsaturated fatty acids (PUFAs) in Western diets may contribute to impaired postnatal immune development and increased allergy risk. Here, we hypothesize that early supplementation with probiotics and ω-3 PUFAs, starting during pregnancy and continuing during infancy, may promote appropriate immune maturation and thereby potentially prevent allergy development. Methods In this study, 117 mother‒baby pairs were randomized into four groups receiving the following supplements: Limosilactobacillus reuteri (L. reuteri), ω-3 PUFA, double supplementation, or placebo. Supplementation started from gestational week 20 until 3 months of age (3 mo) for ω-3 PUFA and continued until 12 mo for L. reuteri. Peripheral blood mononuclear cells (PBMCs) from infants were isolated at birth and at 6, 12, and 24 mo, and stimulated ex vivo with several allergens and ligands of Toll-like receptors (TLRs). Cytokines and chemokines related to Th1/Th2/Th17/Treg responses were quantified. Results Probiotic supplementation modulated the pattern of cytokine and chemokine secretion over time, whereas no clear effects were observed for ω-3 PUFA supplementation. L. reuteri supplementation led to a significant increase in Th1-associated C-X-C motif chemokine ligand 10 (CXCL10) levels induced by birch and cat allergens at 6 mo. Furthermore, L. reuteri induced more significant age-dependent changes under several types of stimulation than did the placebo, indicating enhanced immune maturation. Conclusion Pre- and postnatal probiotic supplementation may promote immune maturation during early childhood.